SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-034364
Filing Date
2019-09-09
Accepted
2019-09-09 16:18:05
Documents
51
Period of Report
2019-07-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-10q_20190731.htm 10-Q 1109796
2 EX-31.1 kalv-ex311_6.htm EX-31.1 21433
3 EX-31.2 kalv-ex312_10.htm EX-31.2 18919
4 EX-32.1 kalv-ex321_8.htm EX-32.1 8650
  Complete submission text file 0001564590-19-034364.txt   4090429

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT kalv-20190731.xml EX-101.INS 821248
6 XBRL TAXONOMY EXTENSION SCHEMA kalv-20190731.xsd EX-101.SCH 35545
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kalv-20190731_cal.xml EX-101.CAL 57815
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kalv-20190731_def.xml EX-101.DEF 78992
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20190731_lab.xml EX-101.LAB 271986
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20190731_pre.xml EX-101.PRE 197289
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 191083235
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences